Aurinia Pharmaceuticals (AUPH) Tops Q4 EPS by 9c

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q4 EPS of ($0.05), $0.09 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $50.03 thousand versus the consensus estimate of $40 thousand.

For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.

You May Also Be Interested In

• Is the global equity rally broadening? UBS weighs in
• Piper Sandler Reiterates Overweight Rating on Patterson-UTI Energy (PTEN)
• BofA says momentum style supported by earnings revisions